Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer

Genentech, a unit of Roche Holdings AG RHHBY, announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis.
The study evaluates Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence.
The Tecentriq combination showed a statistically significant improvement in RFS in the intention-to-treat population of HCC patients with an increased risk of recurrence following resection or ablation with curative intent, compared with active surveillance.
Overall survival data were immature at the interim analysis, and follow-up will continue to the next analysis.
Safety for Tecentriq and Avastin was consistent with the known safety profile of each therapeutic agent and with the underlying disease.
Results from the IMbrave050 study will be discussed with health authorities and presented at an upcoming medical meeting.
The IMbrave050 study randomized 662 people.
Genentech has an extensive development program for Tecentriq, alone and in combination, including multiple ongoing and planned Phase 3 studies across different lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.
Price Action: RHHBY shares closed lower by 0.45% at $39.73 on Wednesday.
Photo Via Company